Applied DNA Sciences (APDN) stock price, revenue, and financials

Applied DNA Sciences market cap is $39.3 m, and annual revenue was $5.39 m in FY 2019

$39.3 M

APDN Mkt cap, 25-Sept-2020

$431.5 K

Applied DNA Sciences Revenue Q3, 2020
Applied DNA Sciences Gross profit (Q3, 2020)276.7 K
Applied DNA Sciences Gross profit margin (Q3, 2020), %64.1%
Applied DNA Sciences Net income (Q3, 2020)-3.3 M
Applied DNA Sciences EBIT (Q3, 2020)-3.2 M
Applied DNA Sciences Cash, 30-Jun-202010.9 M
Applied DNA Sciences EV31.4 M

Applied DNA Sciences Income Statement

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

229.7k516.9k518.4k528.6k317.7k344.6k644.8k597.4k637.1k841.2k1.2m1.5m2.3m1.3m573.3k652.9k903.0k905.4k1.8m647.7k1.0m1.0m884.3k778.5k2.1m633.5k552.5k431.5k

Cost of goods sold

121.3k274.8k297.4k232.3k331.4k372.2k252.6k153.5k133.1k270.9k232.0k179.6k154.8k

Gross profit

531.6k628.2k608.0k1.6m316.2k671.8k763.8k730.8k645.3k1.8m401.5k372.9k276.7k

Gross profit Margin, %

81%70%67%87%49%64%75%83%83%87%63%67%64%

Sales and marketing expense

13.2k37.5k99.4k21.8k

R&D expense

48.0k78.5k96.1k100.0k147.7k176.5k185.0k459.3k359.8k266.3k278.3k373.4k310.1k471.9k729.1k1.1m518.6k635.9k603.1k740.1k669.8k625.0k709.6k651.4k719.7k564.4k703.0k814.6k

General and administrative expense

1.6m2.2m1.8m1.8m2.5m2.8m3.2m3.8m3.3m2.9m4.7m2.9m3.5m3.6m3.1m2.7m3.9m3.2m3.4m2.6m2.0m2.9m3.1m2.5m2.4m2.4m2.3m2.6m

Operating expense total

1.6m2.2m1.9m1.9m2.7m3.0m3.4m4.3m3.7m3.2m4.9m3.3m3.8m4.0m3.8m4.0m4.6m4.0m4.2m3.5m2.8m3.6m3.9m3.3m3.2m3.0m3.1m3.5m

Depreciation and amortization

105.2k106.8k113.4k109.7k123.1k121.3k218.3k171.0k168.6k162.0k163.4k161.4k157.6k145.3k123.0k135.1k97.7k87.3k75.1k66.5k61.9k

EBIT

(1.5m)(1.8m)(1.5m)(1.4m)(2.4m)(2.6m)(2.8m)(3.8m)(3.1m)(2.5m)(3.8m)(1.9m)(1.7m)(2.9m)(3.4m)(3.4m)(4.0m)(3.4m)(2.6m)(3.2m)(2.1m)(2.9m)(3.2m)(2.6m)(1.4m)(2.6m)(2.7m)(3.2m)

EBIT margin, %

(649%)(351%)(290%)(270%)(747%)(757%)(441%)(638%)(491%)(296%)(307%)(124%)(74%)(221%)(601%)(524%)(438%)(378%)(145%)(490%)(205%)(282%)(361%)(338%)(70%)(412%)(485%)(739%)

Interest expense

664.0k597.5k42.8k2.4k405.0333.0434.0239.0111.031.9k16.05.1k2.8k4.1k2.7k1.3k1.2k228.031.6k37.4k38.2k29.1k29.1k28.6k

Pre tax profit

(2.2m)(2.4m)(1.5m)(1.4m)(8.7m)(3.1m)(2.1m)(6.3m)(2.8m)(1.9m)(7.8m)(1.9m)(1.7m)(2.9m)(3.5m)(3.4m)(4.0m)(3.4m)(2.6m)(3.2m)(2.1m)(2.9m)(3.2m)(2.7m)(1.5m)(2.7m)(3.0m)(3.3m)

Income tax expense

Net Income

(2.2m)(2.4m)(1.5m)(1.4m)(8.7m)(3.1m)(2.1m)(6.3m)(2.8m)(1.9m)(7.8m)(1.9m)(1.7m)(2.9m)(3.5m)(3.4m)(4.0m)(3.4m)(2.6m)(3.2m)(2.1m)(2.9m)(3.2m)(2.7m)(1.5m)(2.7m)(3.0m)(3.3m)

Applied DNA Sciences Balance Sheet

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

12.5k1.9m856.6k1.3m984.4k4.4m1.8m4.2m2.0m2.0m2.9m984.1k10.7m12.4m9.8m7.1m6.7m4.0m2.4m4.8m3.7m2.5m3.1m1.5m507.1k8.7m8.7m10.9m

Accounts Receivable

177.8k232.6k323.6k442.8k361.8k407.8k587.7k749.4k606.0k518.3k1.1m1.2m2.1m3.9m5.0m4.8m6.2m5.2m4.7m2.2m1.5m1.4m614.8k316.2k243.6k274.0k549.1k231.2k

Prepaid Expenses

102.7k49.9k23.5k107.7k52.4k25.3k141.6k126.4k108.2k170.8k149.1k155.6k209.8k187.4k126.4k136.8k133.2k182.8k113.2k540.0k575.4k602.8k622.2k591.1k544.5k618.1k678.1k554.7k

Inventories

126.9k323.3k353.6k376.5k314.1k293.8k295.3k225.3k314.7k309.7k82.7k88.9k444.6k

Current Assets

293.0k2.2m1.2m1.8m1.4m4.8m2.6m5.1m2.7m2.7m4.1m2.3m13.0m16.5m14.9m12.1m13.3m9.7m8.1m7.8m6.1m4.8m4.6m2.8m1.6m9.6m10.0m12.2m

PP&E

81.7k121.1k127.3k189.9k198.1k664.1k716.8k647.5k649.4k520.7k587.6k526.8k561.9k879.2k805.8k723.8k672.3k589.7k500.5k550.9k535.8k369.1k315.8k265.3k184.1k265.4k750.5k

Goodwill

285.4k285.4k285.4k285.4k285.4k285.4k285.4k285.4k285.4k285.4k285.4k285.4k285.4k285.4k285.4k

Total Assets

893.6k2.5m1.5m2.0m1.6m5.1m3.8m6.2m3.8m3.8m5.0m3.6m14.1m20.5m17.7m15.2m16.8m13.2m10.4m9.6m7.9m6.6m6.1m4.2m3.0m10.9m11.3m14.0m

Accounts Payable

1.3m787.2k388.2k213.7k602.7k684.9k1.2m769.9k986.3k904.8k885.8k997.7k770.4k1.6m1.9m1.5m1.7m1.2m1.0m602.2k439.2k386.9k944.1k641.7k839.5k832.7k700.0k1.1m

Short-term debt

9.1m9.2m9.3m(3.8m)19.5k279.7k302.6k325.6k284.8k353.8k491.9k485.0k545.9k607.0k1.5m

Current Liabilities

4.9m3.9m638.2k653.9k808.8k809.7k1.5m1.5m1.7m1.6m1.7m1.7m1.6m2.2m2.7m3.0m4.0m3.2m2.4m3.1m2.7m2.2m2.0m1.5m1.8m2.4m

Long-term debt

1.5m1.5m

Total Debt

9.1m9.2m9.3m(3.8m)19.5k279.7k302.6k325.6k284.8k353.8k491.9k485.0k545.9k607.0k1.5m3.0m

Total Liabilities

4.4m4.1m3.5m1.7m1.7m1.6m2.5m2.7m3.0m4.6m3.9m2.4m1.5m2.2m3.5m5.4m5.0m4.8m3.6m4.1m5.2m

Common Stock

352.5k513.2k591.4k627.0k656.9k684.5k733.5k807.9k808.6k827.3k17.4k17.4k21.5k24.1k24.1k24.1k26.4k26.4k27.4k30.1k30.1k30.1k35.6k37.7k38.3k3.5k4.1k5.0k

Additional Paid-in Capital

153.1m162.4m166.0m167.9m170.4m176.4m184.5m194.1m194.6m197.1m210.9m211.4m223.6m232.5m233.0m233.6m239.9m240.5m242.8m248.0m247.7m247.9m251.8m253.0m253.4m266.7m269.7m274.5m

Retained Earnings

(157.4m)(164.3m)(165.8m)(167.2m)(177.7m)(180.8m)(183.0m)(193.0m)(195.7m)(197.7m)(207.6m)(209.5m)(211.1m)(214.6m)(218.0m)(221.4m)(227.8m)(231.2m)(233.8m)(239.9m)(242.0m)(244.9m)(251.1m)(253.8m)(255.3m)(259.5m)(262.4m)(265.7m)

Total Equity

(4.0m)(1.4m)813.8k1.3m(6.7m)(3.8m)2.3m1.9m(320.2k)311.2k3.3m2.0m12.5m18.0m15.0m12.2m12.2m9.3m8.0m8.1m5.7m3.1m766.0k(734.4k)(1.8m)7.2m7.3m8.8m

Financial Leverage

-0.2 x-1.9 x1.8 x1.5 x-0.2 x-1.3 x1.7 x3.3 x-11.8 x12.1 x1.5 x1.9 x1.1 x1.1 x1.2 x1.2 x1.4 x1.4 x1.3 x1.2 x1.4 x2.2 x8 x-5.8 x-1.7 x1.5 x1.6 x1.6 x

Applied DNA Sciences Cash Flow

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(6.1m)(2.4m)(4.0m)(5.4m)(8.7m)(11.8m)(14.0m)(6.3m)(9.0m)(11.0m)(7.8m)(9.7m)(11.4m)(2.9m)(6.4m)(9.8m)(4.0m)(7.4m)(10.0m)(3.2m)(5.3m)(8.2m)(3.2m)(5.9m)(7.4m)(2.7m)(5.6m)

Depreciation and Amortization

276.6k98.4k197.1k300.4k21.0k42.8k105.1k105.2k212.0k325.4k109.7k232.8k354.1k218.3k389.3k558.0k162.0k325.3k486.8k157.6k302.9k425.9k135.1k232.7k320.0k75.1k141.6k203.5k

Accounts Receivable

(114.8k)(24.0k)(115.1k)(234.2k)(64.8k)(110.8k)(360.7k)(91.7k)50.5k137.5k(282.5k)(328.3k)(1.3m)(4.5k)380.4k171.0k828.1k1.7m1.6m432.2k1.0m1.2m879.8k1.2m1.3m566.0k290.8k586.9k

Inventories

(136.8k)(26.1k)(55.8k)(78.8k)12.4k32.6k31.2k(3.9k)(93.3k)(88.4k)59.9k53.7k(302.0k)

Accounts Payable

348.8k19.1k(379.8k)(389.2k)216.8k217.7k616.1k234.7k344.6k292.5k(254.0k)(298.6k)(75.5k)(320.8k)(458.8k)(589.7k)(124.1k)(414.8k)(418.7k)(39.7k)62.9k284.6k198.7k157.5k384.6k(793.9k)(424.6k)(402.8k)

Cash From Operating Activities

(2.2m)(811.5k)(1.8m)(3.0m)(1.7m)(3.9m)(5.7m)(2.1m)(4.3m)(6.3m)(2.4m)(4.0m)(5.2m)(2.7m)(5.2m)(7.5m)(2.1m)(4.7m)(6.6m)(2.6m)(3.3m)(4.4m)(1.5m)(3.8m)(5.1m)(2.7m)(5.2m)(8.2m)

Purchases of PP&E

(47.1k)(65.8k)(30.1k)(213.5k)(94.5k)(109.6k)(209.5k)(30.8k)(197.9k)(221.7k)(51.8k)(128.4k)(594.8k)(42.6k)(93.7k)(111.3k)(48.3k)(203.5k)(269.5k)(52.1k)(64.0k)(68.5k)(8.2k)(19.7k)

Cash From Investing Activities

(47.1k)(65.8k)(30.1k)(797.6k)(94.5k)(109.6k)(209.5k)(30.8k)(232.9k)(459.7k)(66.1k)(160.2k)(632.7k)(42.6k)(93.7k)(111.3k)(48.3k)(203.5k)(269.5k)(52.1k)(64.0k)(68.5k)(44.8k)(56.2k)

Short-term Borrowings

(107.8k)

Cash From Financing Activities

2.2m1.5m2.0m7.6m7.6m2.1m3.9m3.8m15.0m7.9m7.9m7.9m4.3m4.3m4.6m4.4m4.2m4.2m3.0m3.7m4.0m10.8m13.3m18.6m

Net Change in Cash

(5.2k)(811.5k)(1.9m)(1.5m)259.6k3.7m1.1m(2.2m)(4.4m)(4.3m)1.5m(409.1k)9.3m5.1m2.5m(225.4k)2.2m(458.9k)(2.1m)1.8m749.6k(445.0k)1.5m(118.4k)(1.2m)8.1m8.1m10.4m

Interest Paid

45.4k

Income Taxes Paid

4.9k

Applied DNA Sciences Ratios

USDQ3, 2011

Financial Leverage

-0.2 x